权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

REGULATION OF CHRNA7 EXPRESSION

CHRNA7表达的调控

基本信息

批准号：
8120337
负责人：
ROBERT R FREEDMAN
金额：
$ 24.48万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-08-01 至 2014-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8120337
关键词：
3&apos Untranslated Regions Adult Affect Agonist Amino Acids Animal Model Auditory Autopsy Basic Science Biological Assay Brain Cell membrane Choline DBA/2 Mouse DNA-Protein Interaction Development Electrophoretic Mobility Shift Assay Ethnic group Family Functional disorder Gene Deletion Gene Expression Genes Genetic Genetic Polymorphism Genomics Genotype Heterogeneity Hippocampus (Brain)Human Impaired cognition Individual Infant Development Instruction Intervention Investigation Link Luciferases Microarray Analysis Molecular Biology Mus Mutation NRG1 gene National Institute of Mental Health Neuregulins Neurons Nicotinic Receptors Nucleic Acid Regulatory Sequences Nutrient Perinatal Persons Pharmaceutical Preparations Pharmacogenetics Preventive Intervention Principal Investigator Psychotic Disorders Regulation Reporter Research Personnel Research Support Risk Schizophrenia Screening procedure Symptoms Transgenic Mice Treatment outcome analog base design drug development endophenotype experience genetic analysis genetic linkage improved in vitro Assay infancy mouse model new therapeutic target novel therapeutics prevent promoter protein structure sensory gating transmission process

项目摘要

Project 3 identified CHRNA7 as the gene that is linked to the PSO sensory gating abnormality in schizophrenia and found functional SNPs in the core promoter of the gene that are associated with this abnormality. Genetic linkage to 15q13.3, the locus of CHRNA7 has been found in multiple ethnic groups, and recent evidence suggests that rare deletions of the gene are associated with schizophrenia. The human molecular biology studies in this Project characterize mutation, function, and regulation of CHRNA7. To fulfill the need for clinically useful genomics, the human molecular biology project has undertaken extensive screening of CHRNA7 to find its pathogenic mutations. A critical finding is that the amino acid structure of the protein is generally normal in schizophrenia and thus most abnormalities involve regulation of its expression. Project 1 has used that information to design a new therapeutic. Project 3 will continue to support drug development by identifying new polymorphisms, one of which already shows preliminary evidence of a pharmacogenetic effect. Investigation of the 5' and 3' regulatory regions in Aim 1 interacts with similar efforts of Project 4 in DBA/2 mice, which also have CHRNA7 mutations. Functional mutations in human CHRNA7 \N'\\\ be introduced into transgenic mouse models in Project 5. Genotypes may eventually identify individuals who are likely to have genetically determined pathobiology involving a7nAChRs. Project 2's preventive intervention in infancy similarly requires information about CHRNA7 and other genes that convey risk for schizophrenia such as NRG1, a gene associated with risk for schizophrenia that is involved in the developmental expression of aTnAChRs. Aim 2 will determine how NRG1 and CHRNA7 polymorphisms both act to increase risk for schizophrenia. Psychiatric molecular biology in the Center includes more than genomics. Project 2 is now involved in perinatal treatment with choline as an a7nAchR agonist. In Aim 3, Project 3 will contribute its microarray technology to characterize the changes in gene expression that result in animal models from Projects 4-6 that receive this treatment. Results will be compared with our previous experience in characterizing gene expression in postmortem brain from persons who had schizophrenia. Project 3 provides basic research support to Projects 1 and 2 and interacts with basic researchers in Proiects 4, 5, and 6. It receives statistical qenetics support from Core B. RELEVANCE (See instructions): New therapeutic strategies for schizophrenia are needed to improve cognitive dysfunction and negative symptoms and to prevent the development of psychosis. The Center investigates a nicotinic acetylcholine receptor as a new therapeutic target. Investigational results are used to design a new drug treatment for schizophrenia and a preventative nutrient intervention during infant development, both of which activate this ri^r.e^riirsr

项目3发现CHRNA7是与PSO感觉门控异常相关的基因